Vitiligo

Back

Practice Essentials

Vitiligo is an acquired pigmentary disorder of the skin that is characterized by circumscribed, depigmented macules and patches. The condition is frequently associated with disorders of autoimmune origin, with thyroid abnormalities being the most common. See the image below.



View Image

Trichrome vitiligo.

Signs and symptoms

Vitiligo lesions are characterized as follows:

Initial lesions occur most frequently on the hands, forearms, feet, and face, favoring a perioral and periocular distribution.

Clinical variants

See Presentation for more detail.

Diagnosis

Although the diagnosis of vitiligo generally is made on the basis of clinical findings, biopsy is occasionally needed for differentiating vitiligo from other hypopigmenting or depigmenting disorders.

Microscopic examination of involved skin shows a complete absence of melanocytes in association with a total loss of epidermal pigmentation. Superficial perivascular and perifollicular lymphocytic infiltrates may be observed at the margin of vitiliginous lesions, consistent with a cell-mediated process destroying melanocytes.

Other documented histologic findings include the following:

Loss of pigment and melanocytes in the epidermis is highlighted by Fontana-Masson staining and immunohistochemistry testing.[2, 3]

See Workup for more detail.

Management

Nonsurgical treatments

Surgery

The basic types of repigmentation surgery include the following[6, 7] :

See Treatment and Medication for more detail.

Background

Vitiligo is a pigmentary disorder of the skin, which is characterized by circumscribed depigmented macules and patches. Vitiligo is a progressive disorder in which some or all of the melanocytes in the affected skin are selectively destroyed. Vitiligo affects 0.5-2% of the world population, and the average age of onset is 20 years. While vitiligo may be more obvious in patients with darker skin, this disorder does not have a racial or ethnic predilection.[8]

Pathophysiology

Vitiligo is a multifactorial polygenic disorder with a complex pathogenesis. It is related to both genetic and nongenetic factors. Although several theories have been proposed about the pathogenesis of vitiligo, the precise cause remains unknown. Generally agreed upon principles are an absence of functional melanocytes in vitiligo skin and a loss of histochemically recognized melanocytes, owing to their destruction. However, the destruction is most likely a slow process resulting in a progressive decrease of melanocytes. Theories regarding destruction of melanocytes include autoimmune mechanisms, cytotoxic mechanisms, intrinsic melanocyte defects, oxidant-antioxidant mechanisms, and neural mechanisms, as follows:

Because none of these theories alone is entirely satisfactory, some have suggested a composite hypothesis.

Genetics of vitiligo

Vitiligo is characterized by incomplete penetrance, multiple susceptibility loci, and genetic heterogeneity.[14] Family and twin studies have shown that inheritance is complex and likely involves both genetic and environmental factors.[15] Additionally, it is believed that genetic factors may influence the age of onset of vitiligo.[16] The inheritance of vitiligo may include genes associated with the biosynthesis of melanin, a response to oxidative stress, and regulation of autoimmunity.[17]

Current research has not identified any associations with a certain human leukocyte antigen (HLA) type in a consistent manner. There is reason to believe that segmental vitiligo and nonsegmental vitiligo may have distinct genetic mechanisms, which could account for their different responses to treatment.

Epidemiology

In the United States, the relative rate of vitiligo is 1%. Vitiligo is relatively common globally, with a rate of 1-2%. Approximately 30% of vitiligo cases occur with a familial clustering of cases.

A female preponderance has been reported for vitiligo, but it is not statistically significant and the discrepancy has been attributed to an increase in reporting of cosmetic concerns by female patients.

Although vitiligo may appear at any time from birth to senescence, onset is most commonly observed in persons aged 10-30 years. The average age of onset for vitiligo is approximately 20 years. The age of onset is unlikely to vary between the sexes.

History

Vitiligo presents as asymptomatic, milky white colored lesions. The lesions may be localized in focal or segmental vitiligo and generalized in non-segmental vitiligo. Universal vitiligo shows generalized depigmentation. Hairs in the affected region may be white, and this is known as leukotrichia. Patients with generalized vitiligo may present with sunburn due to inadvertent sun exposure or actinic keratosis in long-standing vitiligo. Lesions may appear at the site of trauma (koebnerization).

Physical Examination

Vitiligo is almost always diagnosed clinically upon physical examination. Vitiligo manifests as acquired depigmented macules or patches surrounded by normal skin. The macules are chalk or milk-white in color and are well demarcated. Lesions can be round, oval, or linear in shape. The borders may be convex.[1] Lesions enlarge centrifugally over time at an unpredictable rate. Lesions range from millimeters to centimeters in size. A Wood lamp may be necessary to see lesions on patients with lighter skin. Dermoscopy may also help in the diagnosis of vitiligo. It shows diffuse white glow in established lesion;  reverse pigmentary pattern in evolving vitiligo; micro-koebnerization, comet-tail like appearance in unstable vitiligo and reticular pigment network and peri-follicular pigment in stable and repigmenting vitiligo.[18]

The most common sites of vitiligo involvement are the face, neck, forearms, feet, dorsal hand, fingers, and scalp. When found on the face, lesions may favor a periocular or perioral distribution. In the setting of widespread or generalized vitiligo, lesions may also occur around the genital region, areola, and nipple. Additionally, lesions may occur in regions frequently subjected to trauma, such as bony prominences, elbows, and knees. Koebner phenomenon is defined as the development of vitiligo in sites of trauma, such as a cut, burn, or abrasion. Koebnerization may occur in as many as 20-60% of vitiligo patients.[19]

Body hair in vitiliginous macules may be depigmented. This is known as leukotrichia, and it may indicate a poor prognosis with regard to repigmentation therapy.[20] Spontaneous repigmentation of depigmented hair is unlikely to occur.

Clinical Variants

Trichrome vitiligo is a clinical variant characterized by an intermediate zone of hypopigmentation located between the depigmented center and the peripheral unaffected skin. The natural evolution of the hypopigmented areas is progression to full depigmentation. This results in 3 shades of color in the same patient, as in the image below. The presentation and shades of trichrome vitiligo vary depending on the natural skin color of the patient.



View Image

Trichrome vitiligo.

Marginal inflammatory vitiligo is a very rare variant in which a red, raised border is present at onset or may appear several months or years after initial onset. Mild pruritus may be present. See image below.



View Image

Marginal inflammatory vitiligo.

Quadrichrome vitiligo is another variant of vitiligo, which reflects the presence of a fourth color (dark brown) at sites of perifollicular repigmentation. 

Blue vitiligo is a variant of vitiligo in which a bluish tinge is seen in the depigmented macule. This bluish hue is due to the presence of dermal melanophages. [21]

Clinical Classifications of Vitiligo

Vitiligo may be divided into 2 groups: segmental and nonsegmental. It is important to note that other classification systems exist that choose to break down types of vitiligo based on having a localized or generalized distribution, with localized implying the lesion is restricted to a specific area and generalized implying more than one area is involved. However, the distinction between segmental and nonsegmental may be the most useful to the clinician, as it has an impact on progression, prognosis, and treatment.

Segmental vitiligo

This type manifests as 1 or more macules that may follow the lines of Blaschko. It is unilateral and does not cross the midline. Segmental vitiligo usually has an early onset and rapidly spreads in the affected area. The course of segmental vitiligo can arrest, and depigmented patches can persist unchanged for the life of the patient. This type of vitiligo is not associated with thyroid or other autoimmune disorders. See the image below.



View Image

Segmental vitiligo.

Nonsegmental vitiligo

Nonsegmental vitiligo has served as an umbrella term to include all types of vitiligo that cannot be classified as segmental vitiligo.[22] Of note, nonsegmental vitiligo is more strongly linked than segmental vitiligo to markers of autoimmunity or inflammation such as halo nevi and thyroid antibodies.[23]

Examples of nonsegmental vitiligo include the following (see the image below):

Subtypes of generalized vitiligo include the following:



View Image

Nonsegmental vitiligo.

Complications

The visual nature of the disease results in severe psychosocial and psychological consequences, especially in individuals with darker skin. It can result in social stigma and depression. 

Inadvertent sun-exposure results in acute sunburn, and chronic sun damage can result in non-melanoma skin cancers 

Laboratory Studies

Although the diagnosis of vitiligo generally is made on the basis of clinical findings, biopsy is occasionally helpful for differentiating vitiligo from other hypopigmentary disorders.

Because of the association with other autoimmune diseases and endocrinopathies, further testing may be necessary in patients with suggestive signs or symptoms to rule out an underlying condition. Vitiligo may be associated with thyroid disease, diabetes mellitus, pernicious anemia, Addison disease, and alopecia areata. Appropriate tests should be performed only in the presence of signs or symptoms of associated disease.[4, 31]

Laboratory work for vitiligo may include the following:

Histologic Findings

Microscopic examination of involved skin shows a complete absence of melanocytes in association with a total loss of epidermal pigmentation. Superficial perivascular and perifollicular lymphocytic infiltrates may be observed at the margin of vitiliginous lesions, consistent with a cell-mediated process destroying melanocytes. Degenerative changes have been documented in keratinocytes and melanocytes in both the border lesions and adjacent skin. Other documented changes include increased numbers of Langerhans cells, epidermal vacuolization, and thickening of the basement membrane. Loss of pigment and melanocytes in the epidermis is highlighted by Fontana-Masson staining and immunohistochemistry testing.[2, 3]

Approach Considerations

Various types of medications, phototherapy, laser therapy, and surgical therapy exist. However, it is important to note that in patients with lighter skin, no intervention may be needed. Instead, diligent sun protection may be the best strategy in order to avoid the surrounding normal skin from becoming more tan and making the lesions more obvious. When therapy is necessary, topical steroids, topical calcineurin inhibitors, and narrow-band ultraviolet (UV)–B phototherapy are widely used and are now considered the mainstays of treatment. However, treatment must be individualized and patients should be made aware of the risks associated with therapy. No single therapy for vitiligo produces predictably good results in all patients, and the response to therapy is highly variable.[32, 33, 34, 35, 36]

Some types of vitiligo or lesions in certain locations may be more or less responsive to treatment. Segmental vitiligo and age of onset younger than 14 years have been associated with more refractory disease.[37]  Segmental vitiligo is more responsive to surgical therapy. 

During therapy, pigment cells arise and proliferate from the pilosebaceous unit, spare epidermal melanocytes,[38] and the border of lesions, and migrate up to 2-4 mm from the edge.

Medical Care

Phototherapy

Phototherapy induces satisfactory repigmentation in a majority of patients with early or localized disease.[4] Prolonged phototherapy courses should be encouraged, as a treatment period of at least 6 months may be necessary to accurately assess the responsiveness to the phototherapy.[39] It should be noted that phototherapy causes the normal skin surrounding the lesions to tan, thereby making the lesion more noticeable. This may be cosmetically unacceptable in some patients; therefore, careful counseling surrounding patient expectations and results is necessary before beginning treatment.

Narrowband UV-B (NB-UVB) is widely used and has become the first choice of phototherapy for adults and children with generalized vitiligo. Wavelengths of 311-312 nm typically are used. Treatment frequency is 2-3 times weekly. This treatment can be safely used in children, pregnant women, and lactating women. However, phototherapy may be difficult in pediatric patients who may be unable to cooperate. Short-term adverse effects of NB-UVB include burning, pruritus, and xerosis.

Psoralen photochemotherapy involves the use of psoralens combined with UV-A radiation and is also known as PUVA. Psoralens can be applied either topically or taken orally, followed by exposure to artificial UV-A radiation or natural sunlight. Adverse effects include phototoxic effects, nausea, and risk of skin cancer.

PUVA has largely been replaced by NB-UVB, which is highly effective and has fewer adverse effects. Literature reviews from 2017 have shown that NB-UVB therapy has an overall better response than therapy with PUVA.[39] Additional advantages of NB-UVB over PUVA include shorter treatment times, no drug costs, no nausea, and no need for subsequent photoprotection.

Laser therapy

The excimer laser produces monochromatic rays at 308 nm to treat limited, stable patches of vitiligo. This new treatment is an efficacious, safe, and well-tolerated treatment for vitiligo. However, therapy is expensive. Localized lesions of vitiligo are treated twice weekly for an average of 24-48 sessions.

Excimer laser has been combined with both topical tacrolimus and short-term systemic corticosteroids in the setting of segmental vitiligo, which is a type known to be more resistant to repigmentation in some patients.[40] Studies suggest that segmental vitiligo has a better repigmentation response with excimer laser treatment used at earlier stages of the disease.[41]

Additionally, the use of khellin 4% ointment in combination with monochromatic excimer light (MEL) at 308 nm has been investigated and may be a valid therapeutic option worthy of consideration in the treatment of vitiligo.[42]

Topical therapies

Steroids

A topical corticosteroid preparation is often chosen as a first-line treatment for localized vitiligo because it is easy and convenient for patients.. The results of therapy have been reported as moderately successful, particularly in patients with localized vitiligo and/or an inflammatory component to their vitiligo. Depending on the area being treated, a moderately potent topical steroid can be applied daily for a period of months and then tapered depending on response. Patients should be monitored closely for the possibility of steroid atrophy. 

Topical Janus kinase (JAK) inhibitors 

Topical JAK inhibitor therapy are an emerging option.[55] Ruxolitinib topical cream gained approval from the FDA in July 2022 for treatment of adults and adolescents aged 12 years and older with nonsegmental vitiligo. Approval was based on data from two Phase 3 trials (TRuE-V1 and TRuE-V2), that evaluated the safety and efficacy of ruxolitinib cream compared with vehicle in more than 600 people.

Topical ruxolitinib resulted in significant improvements in vitiligo area scoring index (VASI), which represent improvements in facial and total body repigmentation at Week 24 (primary analysis) compared with vehicle and in an open-label extension at Week 52. Results at Week 24, which were consistent across both studies, showed approximately 30% of patients treated with topical ruxolitinib achieved at least 75% improvement from baseline in the facial (VASI75), the primary endpoint, compared with approximately 8% and 13% of patients treated with vehicle in TRuE-V1 and TRuE-V2, respectively. At Week 52, approximately 50% of ruxolitinib-treated patients achieved F-VASI75.[56]  

Additionally, at Week 24, more than 15% of patients treated with topical ruxolitinib achieved at least 90% improvement from baseline in F-VASI (F-VASI90), compared with approximately 2% of patients treated with vehicle. At Week 52, the percentage of ruxolitinib-treated patients who achieved F-VASI90 doubled to approximately 30%.[56]  

Calcineurin inhibitors

Topical tacrolimus ointment (0.03% or 0.1%) and pimecrolimus cream are effective therapies for vitiligo, particularly when the disease involves the head and neck. These may be used in combination with topical steroids. Studies have suggested that augmenting topical calcineurin inhibitors with laser therapy or NB-UVB may yield better treatment results.[43, 44]

Vitamin D analogs

Vitamin D analogs, particularly calcipotriol and tacalcitol, have been used as topical therapeutic agents in vitiligo. They target the local immune response and act on specific T-cell activation. They do this by inhibition of the transition of T cells (early to late G1 phase) and inhibition of the expression of various proinflammatory cytokines that encode tumor necrosis factor-alpha and interferon-gamma. These vitamin D3 compounds influence melanocyte maturation and differentiation, in addition to up-regulating melanogenesis through pathways that are activated by specific ligand receptors (eg, endothelin receptor and c-kit).[45] More research is needed to examine the effectiveness of calcipotriol as a treatment for vitiligo, as it remains controversial.[46, 47, 48] Some studies have found that the addition of calcipotriol to combination treatments involving NB-UVB, PUVA, or topical steroids improved repigmentation,[46, 47] while others have found no significant differences.[47, 48] While the role of calcipotriol in vitiligo therapy is still not completely clear, it is more likely that it could act as a supplemental therapy rather than a monotherapy. 

Systemic Therapies

Afamelanotide

Afamelanotide is an emerging treatment for vitiligo that is a long-lasting synthetic analog of alpha-melanocyte–stimulating hormone (α-MSH).[49, 50] Afamelanotide binds to the melanocortin-1 receptor and stimulates melanocyte proliferation and melanogenesis. The premise of the treatment the knowledge that patients with vitiligo exhibit defects in the melanocortin system, which manifest as decreased levels of α-MSH in both systemic circulation and skin lesions.[51] Afamelanotide is delivered as a subcutaneous implant. A 55-patient phase I/II study showed that when used in conjunction with NB-UVB, a 7- to 10-day release implant of 16 mg afamelantotide produced faster repigmentation of facial and upper extremity lesions than NB-UVB alone. Adverse reactions included hyperpigmentation of normal skin, nausea, and abdominal pain.[50, 52]  

Janus kinase (JAK) inhibitor therapy

Oral tofacitinib and other JAK inhibitors have revolutionized the treatment of vitiligo. They are often combined with the other treatment modalities mentioned. Other forms of targeted immunotherapy are also emerging as treatment options.[53, 54]  

Systemic corticosteroid therapy

Systemic steroids (prednisone) have been used, although this treatment method is not recommended owing to its toxicity. Systemic corticosteroids can also be used as twice-weekly pulse therapy. 

Depigmentation therapy

If vitiligo is widespread and attempts at repigmentation do not produce satisfactory results, depigmentation may be attempted in very carefully selected patients.

The long-term social and emotional consequences of depigmentation must be considered. Depigmentation should not be attempted unless the patient fully understands that the treatment results in permanent depigmentation. Some authorities have recommended consultation with a mental health professional to discuss potential social consequences of depigmentation.[60]

A 20% cream of monobenzylether of hydroquinone is applied twice daily for 3-12 months. Burning or itching may occur. Allergic contact dermatitis may be seen.[61] The toxicity of monobenzylether of hydroquinone has been deemed mild; however, no research has been performed on the safety of using the drug over large surface areas of skin to induce widespread pigmentation.[62] Accordingly, it is suggested that depigmentation therapy be limited to the lesions that are most bothersome to the patient, such as ones on the face and hands.

Surgical Care

Surgical alternatives exist for the treatment of vitiligo; however, because of the time-consuming nature of surgical therapies, these treatment regimens are limited to segmental vitiligo or localized vitiligo that is limited to a small region.

Characteristics of vitiligo patients that may be a surgical candidate include the following:

Additionally, to be considered for surgery a lesion must be stable, which is to say that the vitiligo is not actively progressing. The most important factors indicating stability are as follows:

The surgical treatment of vitiligo can be classified according to the type of graft as tissue grafting and cellular grafting technique[63] . The tissue grafting technique includes suction blister grafting, mini-punch grafting and split-thickness graft. The cellular grafting techniques involve non-culture epidermal suspension (NCES), non-cultured outer root sheath follicular suspension and cultured melanocyte grafting. 

Micropigmentation[69] is another option. Tattooing can be used to repigment depigmented skin in dark-skinned individuals. Color matching is difficult, the color tends to fade, and the treatment can possibly provoke the appearance of new lesions. Alternatively, skin can be dyed with dihydroxyacetone preparations, although the color match is often poor.

Consultations

In cases where the patient’s vitiligo may be tied to an autoimmune disease or another underlying condition, referral to the respective specialist may be necessary. Consultation with an ophthalmologist may be warranted in cases with suspected ocular involvement or ocular symptoms. Additionally, psychological needs must be addressed on a continual basis with appropriate referrals to mental health specialists.[70]

Psychological and Social Impact

Because vitiligo affects a person’s physical appearance, there are various associated psychological and social impacts. Higher levels of depression and social anxiety have been reported in patients with vitiligo.[71] Patients may also experience low self-esteem, social stigmatization, shame, avoidance of intimacy, adjustment disorder, fear, suicidal ideation, and other psychiatric morbidities.[72] Lower measures of quality of life have been reported.[73, 74, 75] Specifically, visible vitiligo lesions have been associated with more emotional distress and stigmatization than nonvisible lesions.[76, 77] With regard to the pediatric population, adolescents are more likely to report lower quality-of-life measures and greater psychological and emotional distress than young children.[72, 78]

Guidelines Summary

British Association of Dermatologists

Clinical guidelines on the management of vitiligo released in 2021 by the British Association of Dermatologists include, but are not limited to, the following[79] :

Medication Summary

The topical Janus kinase (JAK) inhibitor, ruxolitinib, is the first drug approved for vitiligo repigmentation. Other drugs (eg, topical corticosteroids, topical calcineurin inhibitors, psoralens, immunomodulators, and vitamin D analogs) have been used for treating vitiligo. 

Ruxolitinib topical (Opzelura)

Clinical Context:  Indicated for topical treatment of nonsegmental vitiligo in adults and adolescents aged 12 years and older. 

Class Summary

Mechanism of action may involve disruption of interferon-gamma signaling and Janus kinase pathways involved in vitiligo.

What is vitiligo?How are vitiligo lesions characterized?Where are initial vitiligo lesions located?What are the clinical variants of vitiligo?How is vitiligo diagnosed?What are the findings of microscopic exam of the skin in vitiligo?What are histologic features of vitiligo?What are the nonsurgical treatment options for vitiligo?What is the role of surgery in the treatment of vitiligo?What is vitiligo?What is the pathophysiology of vitiligo?What is the role of genetics in the pathophysiology of vitiligo?What is the incidence of vitiligo in the US?What is the global incidence of vitiligo?How does the incidence of vitiligo vary by sex?What is the most common age of onset for vitiligo?Which physical findings are characteristic of vitiligo?What are the most common sites of vitiligo?What are findings of body hair characteristic of vitiligo?What is trichrome vitiligo?What is marginal inflammatory vitiligo?What is quadrichrome vitiligo?How is vitiligo classified?What is segmental vitiligo?What is nonsegmental vitiligo?What are the types of nonsegmental vitiligo?What are the subtypes of generalized vitiligo?What are the ocular abnormalities associated with vitiligo?What are the signs and symptoms of Alezzandrini syndrome associated with vitiligo?Which autoimmune conditions are associated with vitiligo?What is the role of melanin in the progression of vitiligo?What causes vitiligo in malignant melanoma?What are the differential diagnoses for Vitiligo?What is the role of biopsy in the workup of vitiligo?What is the role of lab studies in the workup of vitiligo?What are the histologic features of vitiligo?What are the treatment options for vitiligo?What is the role of phototherapy in the treatment of vitiligo?How is narrowband UV-B (NB-UVB) used to treat vitiligo?How is psoralen photochemotherapy (PUVA) used to treat vitiligo?What is the role of psoralen photochemotherapy (PUVA) in the treatment of vitiligo?What is the role of laser therapy in the treatment of vitiligo?What is the efficacy of combined excimer laser, topical tacrolimus, and short-term systemic corticosteroids in the treatment of vitiligo?What is the role of combined khellin 4% ointment and monochromatic excimer light (MEL) in the treatment of vitiligo?What is the role of topical corticosteroid in the treatment of vitiligo?What is the role of calcineurin inhibitors in the treatment of vitiligo?What is the role of vitamin D analogs in the treatment of vitiligo?What is the role of afamelanotide in the treatment of vitiligo?What is the role of Janus kinase (JAK) inhibitor therapy in the treatment of vitiligo?What is the role of systemic corticosteroids in the treatment of vitiligo?What is the role of depigmentation therapy in the treatment of vitiligo?What are the long-term social and emotional consequences of depigmentation as a treatment of vitiligo?How is depigmentation therapy administered for the treatment of vitiligo?What is the role of surgery in the treatment of vitiligo?When should surgery be considered for the treatment of vitiligo?How is lesion stability determined in vitiligo?What are the methods for repigmentation surgery for vitiligo?What is the role of micropigmentation in the treatment of vitiligo?Which specialist consultations may be needed to treat vitiligo?What is the psychological and social effect of vitiligo?What are the goals of drug treatment for vitiligo?

Author

Shekhar Neema, MD, Associate Professor, Department of Dermatology, Armed Forces Medical College, India

Disclosure: Nothing to disclose.

Specialty Editors

David F Butler, MD, Former Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

Disclosure: Nothing to disclose.

Edward F Chan, MD, Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania School of Medicine

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Barbara B Wilson, MD, Edward P Cawley Associate Professor, Department of Dermatology, University of Virginia School of Medicine

Disclosure: Nothing to disclose.

Krista Roncone, University of Virginia School of Medicine

Disclosure: Nothing to disclose.

Mark G Lebwohl, MD, Chairman, Department of Dermatology, Mount Sinai School of Medicine

Disclosure: Received none from Amgen for consultant & investigator; Received none from Novartis for consultant & investigator; Received none from Pfizer for consultant & investigator; Received none from Celgene Corporation for consultant & investigator; Received none from Clinuvel for consultant & investigator; Received none from Eli Lilly & Co. for consultant & investigator; Received none from Janssen Ortho Biotech for consultant & investigator; Received none from LEO Pharmaceuticals for consultant & inves.

Naveed Sami, MD, FAAD, Assistant Professor, Department of Dermatology, University of Alabama School of Medicine

Disclosure: Nothing to disclose.

Vlada Groysman, MD, Medical Director, Cahaba Dermatology and Skin Health Center; Clinical Assistant Professor of Dermatology, University of Alabama at Birmingham School of Medicine

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author, Seung-Kyung Hann, MD, to the development and writing of this article.

References

  1. Ortonne J. Vitiligo and other disorders of Hypopigmentation. Bolognia J, Jorizzo J, Rapini R, eds. Dermatology. 2nd. Spain: Elsevier; 2008. Vol 1: 65.
  2. McKee P, Calonje E, Granter S, eds. Disorders of Pigmentation. Pathology of the Skin with Clinical Correlations. 3rd ed. China: Elsevier Mosby; 2005. Vol 2: 993-7.
  3. Moellmann G, Klein-Angerer S, Scollay DA, Nordlund JJ, Lerner AB. Extracellular granular material and degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo. J Invest Dermatol. 1982 Nov. 79(5):321-30. [View Abstract]
  4. Matz H, Tur E. Vitiligo. Curr Probl Dermatol. 2007. 35:78-102. [View Abstract]
  5. Ezzedine K, Silverberg N. A Practical Approach to the Diagnosis and Treatment of Vitiligo in Children. Pediatrics. 2016 Jul. 138 (1):[View Abstract]
  6. van Geel N, Ongenae K, Naeyaert JM. Surgical techniques for vitiligo: a review. Dermatology. 2001. 202(2):162-6. [View Abstract]
  7. Rusfianti M, Wirohadidjodjo YW. Dermatosurgical techniques for repigmentation of vitiligo. Int J Dermatol. 2006 Apr. 45(4):411-7. [View Abstract]
  8. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011 Sep. 65 (3):473-91. [View Abstract]
  9. Schallreuter KU, Wood JM, Pittelkow MR, et al. Regulation of melanin biosynthesis in the human epidermis by tetrahydrobiopterin. Science. 1994 Mar 11. 263(5152):1444-6. [View Abstract]
  10. Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 2003 Apr. 16(2):90-100. [View Abstract]
  11. Zhang BX, Lin M, Qi XY, Zhang RX, Wei ZD, Zhu J, et al. Characterization of circulating CD8+T cells expressing skin homing and cytotoxic molecules in active non-segmental vitiligo. Eur J Dermatol. 2013 Jun 19. [View Abstract]
  12. Oiso N, Suzuki T, Fukai K, Katayama I, Kawada A. Nonsegmental vitiligo and autoimmune mechanism. Dermatol Res Pract. 2011. 2011:518090. [View Abstract]
  13. Toussaint S, Kamino H. Noninfectous papular and squamous diseases. Elder D, Elenitas R, Jaworsky D, Johnson B Jr. Lever's Histopathology of the Skin. Philadelphia, Pa: Lippincot-Raven; 1997. 154-5.
  14. Spritz RA. The genetics of generalized vitiligo. Curr Dir Autoimmun. 2008. 10:244-57. [View Abstract]
  15. Zhang XJ, Chen JJ, Liu JB. The genetic concept of vitiligo. J Dermatol Sci. 2005 Sep. 39 (3):137-46. [View Abstract]
  16. Jin Y, Birlea SA, Fain PR, et al. Genome-Wide Analysis Identifies a Quantitative Trait Locus in the MHC Class II Region Associated with Generalized Vitiligo Age of Onset. J Invest Dermatol. 2011 Jun. 131(6):1308-12. [View Abstract]
  17. Halder R, Taliaferro S. Vitiligo. Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller A, Lefell D, eds. Fitzpatrick's Dermatology in General Medicine. 7th ed. New York, NY: McGraw-Hill; 2008. Vol 1: 72.
  18. Dev A, Vinay K, Bishnoi A, Kumaran MS, Dogra S, Parsad D. Dermatoscopic assessment of treatment response in patients undergoing autologous non-cultured epidermal cell suspension for the treatment of stable vitiligo: A prospective study. Dermatol Ther. 2021 Sep. 34 (5):e15099. [View Abstract]
  19. van Geel N, Speeckaert R, Taieb A, Picardo M, Böhm M, Gawkrodger DJ, et al. Koebner's phenomenon in vitiligo: European position paper. Pigment Cell Melanoma Res. 2011 Jun. 24 (3):564-73. [View Abstract]
  20. Lee DY, Kim CR, Park JH, Lee JH. The incidence of leukotrichia in segmental vitiligo: implication of poor response to medical treatment. Int J Dermatol. 2011 Aug. 50 (8):925-7. [View Abstract]
  21. Chandrashekar L. Dermatoscopy of blue vitiligo. Clin Exp Dermatol. 2009 Jul. 34 (5):e125-6. [View Abstract]
  22. Hann S-K. Clinical variants of vitiligo. Lotti T, Hercogova J, eds. Vitiligo: Problems and Solutions. New York, NY: Marcel Dekker; 2004. 159-73.
  23. Ezzedine K, Diallo A, Leaute-Labreze C, et al. Multivariate analysis of factors associated with early-onset segmental and nonsegmental vitiligo: a prospective observational study of 213 patients. Br J Dermatol. 2011 Jul. 165(1):44-9. [View Abstract]
  24. Yang Y, Lin X, Fu W, Luo X, Kang K. An approach to the correlation between vitiligo and autoimmune thyroiditis in Chinese children. Clin Exp Dermatol. 2009 Oct 23. [View Abstract]
  25. Rashtak S, Pittelkow MR. Skin involvement in systemic autoimmune diseases. Curr Dir Autoimmun. 2008. 10:344-58. [View Abstract]
  26. Pajvani U, Ahmad N, Wiley A, et al. The relationship between family medical history and childhood vitiligo. J Am Acad Dermatol. 2006 Aug. 55(2):238-44. [View Abstract]
  27. Aydogan K, Turan OF, Onart S, Karadogan SK, Tunali S. Audiological abnormalities in patients with vitiligo. Clin Exp Dermatol. 2006 Jan. 31(1):110-3. [View Abstract]
  28. Ardiç FN, Aktan S, Kara CO, Sanli B. High-frequency hearing and reflex latency in patients with pigment disorder. Am J Otolaryngol. 1998 Nov-Dec. 19(6):365-9. [View Abstract]
  29. Gul U, Kilic A, Tulunay O, Kaygusuz G. Vitiligo associated with malignant melanoma and lupus erythematosus. J Dermatol. 2007 Feb. 34(2):142-5. [View Abstract]
  30. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol. 1983 Nov. 9 (5):689-96. [View Abstract]
  31. Dahir AM, Thomsen SF. Comorbidities in vitiligo: comprehensive review. Int J Dermatol. 2018 May 28. [View Abstract]
  32. Migayron L, Boniface K, Seneschal J. Vitiligo, From Physiopathology to Emerging Treatments: A Review. Dermatol Ther (Heidelb). 2020 Sep 19. [View Abstract]
  33. Machado RD, de Morais MC, da Conceição EC, Vaz BG, Chaves AR, Rezende KR. Crude plant extract versus single compounds for vitiligo treatment: Ex vivo intestinal permeability assessment on Brosimum gaudichaudii Trécul. J Pharm Biomed Anal. 2020 Sep 7. 191:113593. [View Abstract]
  34. Salloum A, Bazzi N, Maalouf D, Habre M. Microneedling in vitiligo: A systematic review. Dermatol Ther. 2020 Sep 17. e14297. [View Abstract]
  35. Sach TH, Thomas KS, Batchelor JM, et al. An economic evaluation of the randomised controlled trial of topical corticosteroid and home-based narrowband UVB for active and limited vitiligo (The HI-Light Trial). Br J Dermatol. 2020 Sep 12. [View Abstract]
  36. Bae JM, Jeong KH, Choi CW, Park JH, Lee HJ, Kim HJ, et al. Development of evidence-based consensus on critical issues in the management of patients with vitiligo: A modified Delphi study. Photodermatol Photoimmunol Photomed. 2020 Aug 9. [View Abstract]
  37. Ohguchi R, Kato H, Furuhashi T, Nakamura M, Nishida E, Watanabe S, et al. Risk factors and treatment responses in patients with vitiligo in Japan-A retrospective large-scale study. Kaohsiung J Med Sci. 2015 May. 31 (5):260-4. [View Abstract]
  38. Schallreuter KU, Bahadoran P, Picardo M, et al. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else?. Exp Dermatol. 2008 Feb. 17(2):139-40; discussion 141-60. [View Abstract]
  39. Bae JM, Jung HM, Hong BY, Lee JH, Choi WJ, Lee JH, et al. Phototherapy for Vitiligo: A Systematic Review and Meta-analysis. JAMA Dermatol. 2017 Mar 29. [View Abstract]
  40. Bae JM, Yoo HJ, Kim H, Lee JH, Kim GM. Combination therapy with 308-nm excimer laser, topical tacrolimus, and short-term systemic corticosteroids for segmental vitiligo: A retrospective study of 159 patients. J Am Acad Dermatol. 2015 May 6. [View Abstract]
  41. Do JE, Shin JY, Kim DY, Hann SK, Oh SH. The effect of 308 nm excimer laser on segmental vitiligo: a retrospective study of 80 patients with segmental vitiligo. Photodermatol Photoimmunol Photomed. 2011 Jun. 27(3):147-51. [View Abstract]
  42. Saraceno R, Nistico SP, Capriotti E, Chimenti S. Monochromatic excimer light 308 nm in monotherapy and combined with topical khellin 4% in the treatment of vitiligo: a controlled study. Dermatol Ther. 2009 Jul-Aug. 22(4):391-4. [View Abstract]
  43. Esfandiarpour I, Ekhlasi A, Farajzadeh S, Shamsadini S. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. J Dermatolog Treat. 2009. 20(1):14-8. [View Abstract]
  44. Njoo MD, Westerhof W. Therapeutic guidelines for vitiligo. Lotti T, Hercogova J, eds. Vitiligo: Problems and Solutions. New York, NY: Marcel Dekker; 2004. 235-52.
  45. Birlea SA, Costin GE, Norris DA. Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets. 2008 Apr. 9(4):345-59. [View Abstract]
  46. Ermis O, Alpsoy E, Cetin L, Yilmaz E. Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study. Br J Dermatol. 2001 Sep. 145 (3):472-5. [View Abstract]
  47. Khullar G, Kanwar AJ, Singh S, Parsad D. Comparison of efficacy and safety profile of topical calcipotriol ointment in combination with NB-UVB vs. NB-UVB alone in the treatment of vitiligo: a 24-week prospective right-left comparative clinical trial. J Eur Acad Dermatol Venereol. 2015 May. 29 (5):925-32. [View Abstract]
  48. Akdeniz N, Yavuz IH, Gunes Bilgili S, Ozaydın Yavuz G, Calka O. Comparison of efficacy of narrow band UVB therapies with UVB alone, in combination with calcipotriol, and with betamethasone and calcipotriol in vitiligo. J Dermatolog Treat. 2014 Jun. 25 (3):196-9. [View Abstract]
  49. Grimes PE, Hamzavi I, Lebwohl M, Ortonne JP, Lim HW. The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo. JAMA Dermatol. 2013 Jan. 149 (1):68-73. [View Abstract]
  50. Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddican M, et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol. 2015 Jan. 151 (1):42-50. [View Abstract]
  51. Graham A, Westerhof W, Thody AJ. The expression of alpha-MSH by melanocytes is reduced in vitiligo. Ann N Y Acad Sci. 1999 Oct 20. 885:470-3. [View Abstract]
  52. Dillon AB, Sideris A, Hadi A, Elbuluk N. Advances in Vitiligo: An Update on Medical and Surgical Treatments. J Clin Aesthet Dermatol. 2017 Jan. 10 (1):15-28. [View Abstract]
  53. Kim KI, Jo JW, Lee JH, Kim CD, Yoon TJ. Induction of pigmentation by a small molecule tyrosine kinase inhibitor nilotinib. Biochem Biophys Res Commun. 2018 Jun 28. [View Abstract]
  54. Bunker CB, Manson J. Vitiligo remitting with tocilizumab. J Eur Acad Dermatol Venereol. 2018 Jun 10. [View Abstract]
  55. White C, Miller R. A Literature Review Investigating the Use of Topical Janus Kinase Inhibitors for the Treatment of Vitiligo. J Clin Aesthet Dermatol. 2022 Apr. 15 (4):20-25. [View Abstract]
  56. Focht M. FDA Approves Topical Ruxolitinib (Opzelura) for Nonsegmental Vitiligo. Medscape Medical News. Available at https://www.medscape.com/viewarticle/977464. 2022 July 19; Accessed: July 19, 2022.
  57. Jancin B. Vitiligo: First-ever RCT is smashing success. MDedge.com/dermatology. Available at https://www.mdedge.com/dermatology/article/211169/pigmentation-disorders/vitiligo-first-ever-rct-smashing-success. October 29, 2019; Accessed: October 31, 2019.
  58. Berbert Ferreira S, Berbert Ferreira R, Neves Neto AC, Assef SMC, Scheinberg M. Topical Tofacitinib: A Janus Kinase Inhibitor for the Treatment of Vitiligo in an Adolescent Patient. Case Rep Dermatol. 2021 Jan-Apr. 13 (1):190-194. [View Abstract]
  59. Mobasher P, Guerra R, Li SJ, Frangos J, Ganesan AK, Huang V. Open-label pilot study of tofacitinib 2% for the treatment of refractory vitiligo. Br J Dermatol. 2020 Apr. 182 (4):1047-1049. [View Abstract]
  60. Grau C, Silverberg NB. Vitiligo patients seeking depigmentation therapy: a case report and guidelines for psychological screening. Cutis. 2013 May. 91(5):248-52. [View Abstract]
  61. Chimento SM, Newland M, Ricotti C, Nistico S, Romanelli P. A pilot study to determine the safety and efficacy of monochromatic excimer light in the treatment of vitiligo. J Drugs Dermatol. 2008 Mar. 7(3):258-63. [View Abstract]
  62. AlGhamdi KM, Kumar A. Depigmentation therapies for normal skin in vitiligo universalis. J Eur Acad Dermatol Venereol. 2011 Jul. 25 (7):749-57. [View Abstract]
  63. Ju HJ, Bae JM, Lee RW, Kim SH, Parsad D, Pourang A, et al. Surgical Interventions for Patients With Vitiligo: A Systematic Review and Meta-analysis. JAMA Dermatol. 2021 Mar 1. 157 (3):307-316. [View Abstract]
  64. van Geel N, Wallaeys E, Goh BK, De Mil M, Lambert J. Long-term results of noncultured epidermal cellular grafting in vitiligo, halo naevi, piebaldism and naevus depigmentosus. Br J Dermatol. 2010 Dec. 163(6):1186-93. [View Abstract]
  65. Gupta S, Relhan V, Garg VK, Sahoo B. Autologous noncultured melanocyte-keratinocyte transplantation in stable vitiligo: A randomized comparative study of recipient site preparation by two techniques. Indian J Dermatol Venereol Leprol. 2018 Jul 9. [View Abstract]
  66. Gou D, Currimbhoy S, Pandya AG. Suction blister grafting for vitiligo: efficacy and clinical predictive factors. Dermatol Surg. 2015 May. 41 (5):633-9. [View Abstract]
  67. Bae JM, Lee JH, Kwon HS, Kim J, Kim DS. Motorized 0.8 mm micro-punch grafting for refractory vitiligo: A retrospective study of 230 cases. J Am Acad Dermatol. 2018 Jun 15. [View Abstract]
  68. Falabella R. Surgical approaches for stable vitiligo. Dermatol Surg. 2005 Oct. 31(10):1277-84. [View Abstract]
  69. McGovern TW, Bolognia J, Leffell DJ. Flip-top pigment transplantation: a novel transplantation procedure for the treatment of depigmentation. Arch Dermatol. 1999 Nov. 135(11):1305-7. [View Abstract]
  70. Kovacs SO. Vitiligo. J Am Acad Dermatol. 1998 May. 38(5 Pt 1):647-66; quiz 667-8. [View Abstract]
  71. Salman A, Kurt E, Topcuoglu V, Demircay Z. Social Anxiety and Quality of Life in Vitiligo and Acne Patients with Facial Involvement: A Cross-Sectional Controlled Study. Am J Clin Dermatol. 2016 Jun. 17 (3):305-11. [View Abstract]
  72. Brown MM, Chamlin SL, Smidt AC. Quality of life in pediatric dermatology. Dermatol Clin. 2013 Apr. 31 (2):211-21. [View Abstract]
  73. Bonotis K, Pantelis K, Karaoulanis S, Katsimaglis C, Papaliaga M, Zafiriou E, et al. Investigation of factors associated with health-related quality of life and psychological distress in vitiligo. J Dtsch Dermatol Ges. 2016 Jan. 14 (1):45-9. [View Abstract]
  74. Porter J, Beuf AH, Nordlund JJ, Lerner AB. Psychological reaction to chronic skin disorders: a study of patients with vitiligo. Gen Hosp Psychiatry. 1979 Apr. 1 (1):73-7. [View Abstract]
  75. Silverberg JI, Silverberg NB. Association between vitiligo extent and distribution and quality-of-life impairment. JAMA Dermatol. 2013 Feb. 149 (2):159-64. [View Abstract]
  76. Nogueira LS, Zancanaro PC, Azambuja RD. [Vitiligo and emotions]. An Bras Dermatol. 2009 Jan-Feb. 84 (1):41-5. [View Abstract]
  77. Schmid-Ott G, Künsebeck HW, Jecht E, Shimshoni R, Lazaroff I, Schallmayer S, et al. Stigmatization experience, coping and sense of coherence in vitiligo patients. J Eur Acad Dermatol Venereol. 2007 Apr. 21 (4):456-61. [View Abstract]
  78. Silverberg JI, Silverberg NB. Quality of life impairment in children and adolescents with vitiligo. Pediatr Dermatol. 2014 May-Jun. 31 (3):309-18. [View Abstract]
  79. Eleftheriadou V, Atkar R, Batchelor J, et al. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. Br J Dermatol. 2022 Jan. 186 (1):18-29. [View Abstract]

Trichrome vitiligo.

Trichrome vitiligo.

Marginal inflammatory vitiligo.

Segmental vitiligo.

Nonsegmental vitiligo.

Trichrome vitiligo.

Marginal inflammatory vitiligo.

Segmental vitiligo.

Nonsegmental vitiligo.